Will the FDA approve CagriSema?
As of Fri, 20 Nov 2026 15:50:20 UTC, Kalshi traders price Before Jan 1, 2027 (94.0%), Before Jul 1, 2027 (92.0%), Before Jan 1, 2028 (91.0%). The market has $12K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before Jan 1, 2027 | 94.0% | 94.0¢ | 6.0¢ |
| Before Jul 1, 2027 | 92.0% | 92.0¢ | 8.0¢ |
| Before Jan 1, 2028 | 91.0% | 91.0¢ | 9.0¢ |
Market details
- Venue: Kalshi
- Volume: $12K
- Liquidity: $12K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for Before Jan 1, 2027:
If the FDA approves CagriSema for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete…
Sources
Related markets
- Will the FDA approve retatrutide?
- Tesla Optimus released this year?
- How many launches will SpaceX have this year?
- When will any company achieve AGI?
- How many launches will SpaceX have in November?
- When will Apple release the iPhone 18?
More markets like this
- Will the FDA approve VERVE-102?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)
- FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)
- FDA decision: Oveporexton by Takeda (this year)
- Will the OpenAI/Jony Ive device have a screen?
- Will the South Carolina special Republican primary be won outright?
- Will the US start the process of building a nuclear-powered data center on a military base before 2030?
- Will there be a case of polio in the USA this year?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.